Endocrine Testing Market - Forecasts from 2024 to 2029

The global endocrine testing market was valued at US$11.420 billion in 2022 and is expected to grow at a CAGR of 6.35% over the forecast period to reach a total market size of US$17.574 billion by 2029.

An endocrine system is a set of hormone-producing glands that help regulate different body functions, such as metabolism, sexual development, growth, and weight. Endocrine testing involves assessing hormonal levels to determine how the glands are functioning. Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.

Increased disease incidence has prompted the development of advanced diagnostic technologies, which further increases the need for sophisticated testing methods. While these technologies are likely to gain some attention in the market shortly, significant costs associated with developing them could hamper their rapid commercialization, thus limiting the market’s growth.

Since endocrine testing tools are in high demand, market players are more committed to developing new products. For example, DRG Diagnostics launched free T4 ELISA test kits in October 2018. This ELISA kit is intended to measure free thyroid hormone in human serum directly and quantitatively.

Globally, an increasing number of diabetics, geriatrics, and obese people should promote market growth. In addition, growing health awareness among individuals, along with government support, will increase the number of early diagnoses and thereby contribute to the endocrine testing market growth. The demand for advanced endocrine testing technologies is also expected to grow due to diseases such as hypothyroidism and hyperthyroidism.

Market Drivers:

Tests to measure thyroid-stimulating hormone (TSH) are expected to grow the endocrine testing market.

Pituitary-stimulating hormone (TSH) stimulates the production of thyroxine and triiodothyronine by the thyroid gland, which aids metabolism. The TSH test is used to determine thyroid levels. Over the past decade, thyroid disorders have increased worldwide. According to the American Thyroid Association (ATA), 20 million Americans are estimated to have some form of thyroid disease in 2019. More than 12% of US citizens are expected to suffer from thyroid disease at some point in their lives.

Smoking, alcohol consumption, and tobacco use are the most important risk factors for thyroid-related disorders. In a study conducted in November 2019 by researchers from the Department of Nephrology at the University of Groningen and University Medical Center Groningen, The Netherlands, findings showed that daily cigarette smoking was associated with lower levels of TSH and lower levels of FT4 and FT3.

Technology developments have allowed thyroid function tests to become more cost-effective, and thyroid hormone measurement has recently gained importance. As a result, the rise in TSH testing is expected to boost the global endocrine testing market’s growth.

The rise in the geriatric population worldwide is anticipated to boost the endocrine testing market growth.

In addition to declines in growth hormones associated with aging, changes in the endocrine system include menopause in women, skeletal mass loss, androgen deficiency in men, and an increased incidence of type 2 diabetes. The endocrine system undergoes a series of changes that affect the hormone levels of people as they age. This is why the rise of the global geriatric population is one of the primary factors driving the endocrine testing market’s growth.

According to the United Nations (UN) data on World Population Prospects for 2019, the world's population will double within 30 years, from 7.7 billion to 9.7 billion, and at the same time, the world will age more rapidly. The number of people over the age of 65 will rise from one in 11 in 2019 to one in six by 2050 (16%), up from one in 11 at the beginning of this year (9%). Additionally, 34.2 million Americans (just over one in ten) have diabetes. A third of American adults, approximately 88 million, have prediabetes. (Source: CDC)

Market Restraints:

The high cost of technology could hinder the endocrine testing market growth.

For endocrine testing manufacturers, the high cost of research and development activities and subsequent commercialization of tests represent a serious challenge. Thus, monitoring and diagnosing an individual's hormone secretion levels has become extremely expensive. Roche, for instance, invested approximately USD 11.6 billion in research and development activities in the financial year 2019. A significant portion of Abbott Laboratories' revenues are invested in the research and development of novel products and technologies. As a result, the end product is very expensive, which adds to the cost of diagnostic technologies, which impacts the market negatively.

The North American market is predicted to dominate the global endocrine testing market.

North America's dominance in the global endocrine testing market is attributed to its advanced healthcare infrastructure, technological innovation, high prevalence of endocrine disorders, rising awareness and screening programs, supportive regulatory environment, strong presence of key market players, and high healthcare spending. The United States and Canada have advanced healthcare infrastructure, leading to the adoption and utilization of advanced diagnostic tools and devices.

The high prevalence of endocrine disorders, such as diabetes, thyroid disorders, and hormonal imbalances, is driven by factors such as sedentary lifestyles, poor dietary habits, and an aging population. Increased awareness and screening programs encourage individuals to undergo regular endocrine testing, further boosting demand.

The supportive regulatory environment, overseen by the FDA and Health Canada, fosters innovation and ensures the safety and efficacy of endocrine testing products. The United States' high healthcare expenditures enable individuals and healthcare institutions to invest in advanced diagnostic services, including endocrine testing, further fuelling market growth.

Key Developments:

• November 2023-Novo Nordisk, MEMS, and Roche partnered to launch the Changing Diabetes® in Children (CDiC) project in Malaysia, aiming to improve care for children and young adults below 25 with type 1 diabetes. The initiative provide free glucose monitoring supplies to children and young adults, is a significant step in diabetes management. The initiative also contribute to improving access to care, aligning with this year's World Diabetes Day theme of "Access to Diabetes Care." The initiative aims to improve the quality of care for children and young adults with type 1 diabetes.
• May 2022-Berlin-based Inne.io secured €9.3 million in funding to expand its hormone-tracking tech. The startup aims to address the underfunding of women's healthcare and the desire for personalized and digitalized healthcare. The funding was led by DSM Venturing, Borski Fund, Calm Storm Ventures, and high-profile angels Taavet Hinrikus (Wise), Dr Fiona Pathiraja, and Rolf Schromgens (Trivago). Inne.io aims to offer services to women at all stages of life, addressing the intersectional gap in women's health, particularly older women who are often neglected in healthcare.

Segmentation:

By Technology

• Liquid Chromatography-Mass Spectrometry (LC-MS)
• Immunoassay
• ELISA
• Tandem Mass Spectrometry
• Others

By Application

• Cortisol Test
• Human Chorionic Gonadotropin (HCG) Test
• Dehydroepiandrosterone Sulfate (DHEAS) Test
• Thyroid Stimulating Hormone (TSH) Test
• Prolactin Test
• Insulin
• Others

By End Users

• Hospitals and Clinics
• Diagnostic Centres

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• South Korea
• Taiwan
• Thailand
• Indonesia
• Japan
• Others